secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2024-09-16T23:59:59+00:00
Accession:  0001725160-24-000161
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA lifts partial clinical hold on Zentalis' azenosertib studies; enrollment to resume
--------------------------------------------------------------------------------

- FDA cleared resumption of enrollment in all ongoing azenosertib studies with no changes to the clinical development plan.
- Partial clinical hold was placed June 18, 2024; lifted after FDA review of comprehensive safety assessment.
- Zentalis on track to present azenosertib monotherapy data and additional updates in Q4 2024.
- CEO cites unwavering confidence in azenosertib's therapeutic index for gynecologic malignancies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516024000161/0001725160-24-000161-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516024000161/zntl-20240916.htm
  HTML page:      https://secwatch.observer/filing/0001725160-24-000161

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer